Literature DB >> 18283248

Plasma beta amyloid and cytokine profile in women with Alzheimer's disease.

Agnieszka Baranowska-Bik1, Wojciech Bik, Ewa Wolinska-Witort, Lidia Martynska, Magdalena Chmielowska, Maria Barcikowska, Boguslawa Baranowska.   

Abstract

Alzheimer's disease (AD) belongs to a group of neurodegenerative disorders. It is characterized by irreversible and progressive memory loss accompanied with decline in other cognitive functions. At a microscopic level, the typical neuropathologic features, senile plaques and neurofibrillary lesions are found. The pathological processes lead to neuronal loss, synaptic dysfunction and inappropriate activity of neurotransmitters. The major constituent of senile plaques is abnormally aggregated beta amyloid protein. Beta amyloid (Abeta) is a short (40-42 amino acid) product of proteolysis of the transmembrane amyloid precursor protein (APP). Extracellular depositions of Abeta 1-42 may initiate a wide range of pathological processes including glia activation, neuroinflammation and neuronal apoptosis. There is convincing evidence that inflammatory response to accumulation of beta amyloid plays a pivotal role in the progression of neuropathological changes found in AD. Current research was directed at assessing beta amyloid, cytokines (IL-6, IL-10 and TNF alpha) plasma levels in women with AD. Hundred and twenty four women, aged between 59 to 86 years, were enrolled in the study. Amongst them 57 were diagnosed with AD (29 subjects in early stage and 28 subjects with moderate to severe stadium of disease) and 67 women without dementia were investigated as a control group. The lowest values of Abeta 1-42 were found in AD subjects in moderate to severe stage of disease as compared with the early stage of AD (p< 0.05) and the control group (p<0.01). Change in IL-6 values was significantly different between groups with the lowest values found in women without dementia. Both subset of AD patients demonstrated statistically enhanced IL-6 levels when compared with the control group (p<0.001, p<0.01 respectively for early and moderate/severe stage of AD). Moreover, our study revealed a trend to increase in TNF alfa and IL-10 values in AD. However, those differences were not statistically significant. In addition, we did not detect any correlations between plasma beta amyloid and investigated cytokines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283248

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  18 in total

1.  Semantic integration of data on transcriptional regulation.

Authors:  Michael Baitaluk; Julia Ponomarenko
Journal:  Bioinformatics       Date:  2010-04-28       Impact factor: 6.937

2.  Age-related changes in neural volume and microstructure associated with interleukin-6 are ameliorated by a calorie-restricted diet in old rhesus monkeys.

Authors:  A A Willette; B B Bendlin; D G McLaren; E Canu; E K Kastman; K J Kosmatka; G Xu; A S Field; A L Alexander; R J Colman; R H Weindruch; C L Coe; S C Johnson
Journal:  Neuroimage       Date:  2010-03-15       Impact factor: 6.556

Review 3.  The multifaceted profile of activated microglia.

Authors:  Marina A Lynch
Journal:  Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.590

4.  Astrocytes regulate α-secretase-cleaved soluble amyloid precursor protein secretion in neuronal cells: Involvement of group IIA secretory phospholipase A2.

Authors:  X Yang; W Sheng; D M Ridgley; M A Haidekker; G Y Sun; J C Lee
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

5.  Meta-analysis of plasma amyloid-β levels in Alzheimer's disease.

Authors:  Fei Song; Anne Poljak; Michael Valenzuela; Richard Mayeux; George A Smythe; Perminder S Sachdev
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 6.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

7.  Plasma Biomarkers of Alzheimer's Disease in African Americans.

Authors:  Kaancan Deniz; Charlotte C G Ho; Kimberly G Malphrus; Joseph S Reddy; Thuy Nguyen; Troy P Carnwath; Julia E Crook; John A Lucas; Neill R Graff-Radford; Minerva M Carrasquillo; Nilüfer Ertekin-Taner
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

8.  Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.

Authors:  Paramita Chakrabarty; Karen Jansen-West; Amanda Beccard; Carolina Ceballos-Diaz; Yona Levites; Christophe Verbeeck; Abba C Zubair; Dennis Dickson; Todd E Golde; Pritam Das
Journal:  FASEB J       Date:  2009-10-13       Impact factor: 5.191

9.  The clinical correlation of proinflammatory and anti-inflammatory biomarkers with Alzheimer disease: a meta-analysis.

Authors:  Urati Anuradha; Anoop Kumar; Rakesh Kumar Singh
Journal:  Neurol Sci       Date:  2021-05-25       Impact factor: 3.830

10.  Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease.

Authors:  Onofre Combarros; Cornelia M van Duijn; Naomi Hammond; Olivia Belbin; Alejandro Arias-Vásquez; Mario Cortina-Borja; Michael G Lehmann; Yurii S Aulchenko; Maaike Schuur; Heike Kölsch; Reinhard Heun; Gordon K Wilcock; Kristelle Brown; Patrick G Kehoe; Rachel Harrison; Eliecer Coto; Victoria Alvarez; Panos Deloukas; Ignacio Mateo; Rhian Gwilliam; Kevin Morgan; Donald R Warden; A David Smith; Donald J Lehmann
Journal:  J Neuroinflammation       Date:  2009-08-23       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.